Skip to content

US · TRIB · MEDICAL - DIAGNOSTICS & RESEARCH

Trinity Biotech plc (TRIB) intrinsic value and stock valuation

$6.24as of 2026-11-21 · Mkt cap 251.72M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Trinity Biotech plc DCF and intrinsic value

InvestorsCraft values TRIB with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from TRIB’s statements →

Trinity Biotech plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Bray, WW A98 H5C8 trinitybiotech.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$43.8M-15.6% 5y CAGRd
20112025
Net income
-$-37.38M
20112025
Free cash flow
-$-12.15M
20112025
Total equity
-$-71.98M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$43.8M$61.6M$56.8M$62.5M$81.2M
Operating income-$-11.42M-$-21.16M-$-27.05M-$-15.27M$3.94M
Net income-$-37.38M-$-31.79M-$-24.02M-$-41M$880K
EPSd-$-60.29M-$-52.98M-$-92.38M-$-157.69M$4.89M
Operating cash flow-$-5.93M-$-4.19M-$-11.56M-$-920K$13.2M
Capital expenditure-$-6.22M-$-10.06M-$-800K-$-5.98M-$-8.69M
Free cash flow-$-12.15M-$-14.26M-$-12.36M-$-6.9M$4.55M
Total assets$105.2M$103.3M$59.4M$92.1M$118.9M
Total debt$138M$100.8M$67.4M$72.2M$99.2M
Net debt$132.8M$95.6M$63.7M$51.7M$73.3M
Total equity-$-71.98M-$-35.18M-$-23.95M-$-2.18M-$-320K
Cash and short-term investments$5.14M$5.17M$3.69M$6.58M$25.9M
Income statement
20252024202320222021
Revenue$43.8M$61.6M$56.8M$62.5M$81.2M
Cost of revenue$26.9M$40.1M$37.4M$52.7M$54.9M
Gross profit$16.9M$21.4M$19.5M$22.1M$33.5M
Research and development expenses$3.63M$4.54M$4.38M$4.14M$4.5M
Selling, general and administrative expenses$24.7M$28.8M$31.2M$29.2M$24.7M
Other expenses$0.00$9.25M$11M-$-340K$340K
Operating expenses$28.3M$42.6M$46.5M$33M$29.5M
Cost and expenses$55.2M$82.7M$83.9M$81.9M$77.2M
Interest income$220K$0.00$1.17M$300K$1.22M
Interest expense$13.1M$9.56M$10.2M$24.7M$7.1M
Depreciation and amortization$2.68M$1.86M$1.78M$2.33M$2.74M
Ebitda-$-21.38M-$-16.91M-$-24.1M-$-16.71M$10.6M
Operating income-$-11.42M-$-21.16M-$-27.05M-$-15.27M$3.94M
Total other income/expenses, net-$-25.76M-$-9.56M-$-9.88M-$-24.43M-$-5.86M
Income before tax-$-37.18M-$-30.73M-$-36.93M-$-43.78M-$-1.92M
Income tax expense$200K$490K-$-60K-$-190K-$-70K
Net income-$-37.38M-$-31.79M-$-24.02M-$-41M$880K
Weighted average shares outstanding$620K$600K$260K$220K$140K
Weighted average diluted shares outstanding$620K$600K$260K$260K$180K
Balance sheet
20252024202320222021
Cash and short-term investments$5.14M$5.17M$3.69M$6.58M$25.9M
Net receivables$10.3M$14.6M$13.4M$15.7M$15.7M
Inventory$18.8M$19.4M$19.9M$22.5M$29.1M
Total current assets$35.9M$41.1M$39M$46.7M$72.7M
Property, plant and equipment, net$5.3M$4.62M$1.89M$5.68M$5.92M
Goodwill and intangible assets$57M$51.3M$16.3M$35.3M$36M
Long-term investments$3.02M$2.46M$210K$210K$150K
Total non-current assets$69.3M$62.2M$20.4M$45.4M$46.2M
Total assets$105.2M$103.3M$59.4M$92.1M$118.9M
Accounts payable$11.5M$6.83M$3.88M$6.21M$6.76M
Short-term debt$110.8M$2.5M$1.9M$1.89M$85.3M
Deferred revenue$190K$200K$50K$110K$140K
Total current liabilities$141.2M$32.1M$15M$17.3M$100.5M
Long-term debt$27.2M$98.3M$65.5M$70.3M$13.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$35.9M$106.4M$68.4M$76.9M$18.7M
Capital lease obligations$10.8M$12.8M$12.6M$13.9M$15.9M
Total liabilities$177.2M$138.5M$83.4M$94.3M$119.2M
Common stock$40K$4.19M$1.97M$1.96M$1.21M
Retained earnings-$-116.17M-$-79.12M-$-48.64M-$-26.7M$12.6M
Accumulated other comprehensive income (loss)$5.27M-$-5.44M$1.03M-$-5.69M-$-5.36M
Total equity-$-71.98M-$-35.18M-$-23.95M-$-2.18M-$-320K
Total investments$3.02M$2.46M$210K$210K$150K
Total debt$138M$100.8M$67.4M$72.2M$99.2M
Net debt$132.8M$95.6M$63.7M$51.7M$73.3M
Cash flow statement
20252024202320222021
Net income-$-37.38M-$-31.79M-$-24.02M-$-41.01M$880K
Depreciation and amortization$2.68M$1.86M$1.78M$2.33M$2.74M
Stock-based compensation$320K$1.32M$2.07M$1.75M$1.1M
Change in working capital$7.03M$6.19M-$-2.69M-$-1.66M-$-170K
Accounts receivable$4.92M-$-2.37M$1.05M-$-970K$6.24M
Inventory$90K-$-1.74M-$-970K-$-880K-$-4.41M
Accounts payable$0.00$8.19M-$-2.77M$180K-$-7.59M
Net cash provided by operating activities-$-5.93M-$-4.19M-$-11.56M-$-920K$13.2M
Investments in property, plant and equipment-$-90K-$-410K-$-800K-$-1.1M-$-1.81M
Acquisitions, net$0.00-$-12.9M$28.2M$0.00$0.00
Net cash used for investing activities-$-6.22M-$-22.97M$24.8M-$-5.98M-$-8.69M
Common stock issued$550K$7.39M$0.00$25.3M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.1M$28.8M-$-16.04M-$-12.32M-$-6.02M
Net change in cash-$-30K$1.48M-$-2.89M-$-19.33M-$-1.42M
Cash at end of period$5.14M$5.17M$3.69M$6.58M$25.9M
Operating cash flow-$-5.93M-$-4.19M-$-11.56M-$-920K$13.2M
Capital expenditure-$-6.22M-$-10.06M-$-800K-$-5.98M-$-8.69M
Free cash flow-$-12.15M-$-14.26M-$-12.36M-$-6.9M$4.55M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Trinity Biotech plc

        Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.

        CEO
        John Gillard
        Employees
        287
        Beta
        1.00

        Explore

        Frequently asked questions

        What is the intrinsic value of Trinity Biotech plc (TRIB)?

        Trinity Biotech plc (TRIB) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TRIB undervalued?

        TRIB trades at a price of $6.24 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.